title: Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study.
abstract: OBJECTIVE
  To investigate the recurrence and severity of climacteric symptoms after two methods of discontinuation of prolonged hormone therapy.
  
  
  METHODS
  Postmenopausal women treated with hormone therapy for more than 3 years and opting to discontinue therapy were randomly assigned to two treatment groups. Hormone therapy was discontinued either abruptly (group 1) or gradually (group 2). Symptoms in both groups were monitored with the Greene climacteric scale at 1, 3, 6, 9, and 12 months.
  
  
  RESULTS
  Ninety-one women aged 48 to 73 years (mean age 56.8 +/- 4.2 years) participated in the study. The mean therapy duration was 8.8 +/- 3.8 years. No differences were noted between the two groups regarding age at menopause, body mass index, reasons to start therapy, hormone therapy duration, type of regimen, and reasons cited for hormone treatment discontinuation. After cessation of therapy, a similar percentage of patients in each group resumed hormone therapy. Climacteric syndromes, specifically vasomotor dysfunction, were more severe in group 1 than in group 2 during the first 3 months after hormone therapy withdrawal. However, by 6 months vasomotor symptoms were worse in group 2. By 9 to 12 months, no difference was noted between groups. No differences were observed in the percentage of weight gain, vaginal bleeding, and atrophy after discontinuation of therapy by either method.
  
  
  CONCLUSIONS
  Our specific regimen of gradual discontinuation of hormone therapy merely postponed, and neither prevented nor minimized, the reappearance of vasomotor symptoms, mood deterioration, and sexual dysfunction, and the resulting discomfort.
authors.affiliation: Department of Obstetrics and Gynecology, Hadassah Medical Center, Hebrew University Hospital, Mount Scopus, Jerusalem, Israel. kochman@hadassah.org.il
authors.forename: Ronit
authors.initials: R
authors.lastname: Haimov-Kochman
authors.forename: Edyah
authors.initials: E
authors.lastname: Barak-Glantz
authors.forename: Revital
authors.initials: R
authors.lastname: Arbel
authors.forename: Miriam
authors.initials: M
authors.lastname: Leefsma
authors.forename: Amnon
authors.initials: A
authors.lastname: Brzezinski
authors.forename: Ariel
authors.initials: A
authors.lastname: Milwidsky
authors.forename: Drorith
authors.initials: D
authors.lastname: Hochner-Celnikier
mesh_terms: D000368:Aged; D004334:Drug Administration Schedule; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000008:administration & dosage*; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D011372:Progestins / Q000008:administration & dosage*; D011446:Prospective Studies; D012008:Recurrence; D012720:Severity of Illness Index; D016896:Treatment Outcome; D016312:Treatment Refusal / Q000706:statistics & numerical data
chemical_list: D004967:Estrogens; D011372:Progestins